Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Liabilities and Shareholders Equity (2019 - 2025)

Historic Liabilities and Shareholders Equity for Nurix Therapeutics (NRIX) over the last 7 years, with Q4 2025 value amounting to $688.1 million.

  • Nurix Therapeutics' Liabilities and Shareholders Equity rose 280.75% to $688.1 million in Q4 2025 from the same period last year, while for Nov 2025 it was $2.4 billion, marking a year-over-year increase of 2045.98%. This contributed to the annual value of $688.1 million for FY2025, which is 280.75% up from last year.
  • Latest data reveals that Nurix Therapeutics reported Liabilities and Shareholders Equity of $688.1 million as of Q4 2025, which was up 280.75% from $522.5 million recorded in Q3 2025.
  • Over the past 5 years, Nurix Therapeutics' Liabilities and Shareholders Equity peaked at $688.1 million during Q4 2025, and registered a low of $308.2 million during Q3 2023.
  • Moreover, its 5-year median value for Liabilities and Shareholders Equity was $468.1 million (2021), whereas its average is $470.1 million.
  • Per our database at Business Quant, Nurix Therapeutics' Liabilities and Shareholders Equity crashed by 3290.45% in 2023 and then surged by 9670.42% in 2025.
  • Nurix Therapeutics' Liabilities and Shareholders Equity (Quarter) stood at $476.8 million in 2021, then dropped by 12.59% to $416.8 million in 2022, then dropped by 14.68% to $355.6 million in 2023, then skyrocketed by 88.23% to $669.3 million in 2024, then increased by 2.81% to $688.1 million in 2025.
  • Its Liabilities and Shareholders Equity was $688.1 million in Q4 2025, compared to $522.5 million in Q3 2025 and $591.6 million in Q2 2025.